Treatment of Urethral Cancer: Urothelial Carcinoma of the Prostatic Urethra or Prostatic Ducts at Stage Ta, Tis, or T1

This protocol covers urothelial carcinoma confined to the prostatic urethra or prostatic ducts at early pathological stages (Ta, Tis, or T1) with no regional nodal involvement and no distant metastasis (N0, M0). The depth and pattern of involvement—surface-only versus ductal or stromal extension—is central to management decisions.

For non-invasive disease or carcinoma in situ of the prostatic urethra and prostatic ducts, a urethra-sparing approach combining transurethral resection with bacillus Calmette-Guérin (BCG) instillation is an established strategy. BCG instillation is effective in patients with Ta or Tis prostatic urethral carcinoma when tumour involvement is limited.

When intravesical therapy is insufficient or when ductal or stromal involvement is present, a definitive surgical intervention targeting both the prostate and the regional pelvic lymphatics is indicated—

The complete surgical algorithm, including extent of resection and lymphadenectomy scope, is detailed in the full structured regimen.